170 results
Keyword Keytruda Remove keyword
-
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021
CHMP, Last updated: 17/09/2021Keytruda, … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021
CHMP, Last updated: 01/02/2021Keytruda … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021
CHMP, Last updated: 17/12/2021Keytruda … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022
CHMP, Last updated: 20/05/2022Keytruda … -
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Urologic Neoplasms; Breast Neoplasms; Small Cell Lung Carcinoma
Date of authorisation: 20/09/2017, Revision: 18, Authorised, Last updated: 11/05/202201/06/2018 EMA restricts use of Keytruda and Tecentriq in bladder … -
List item
National expert: Anne-Berit Erdal, Norwegian Medicines Agency (updated)
- Declaration of interests - 80.78 KB | PDF
- Curriculum Vitae - 17.07 KB | PDF
line 05/2017-08/2019 MSD Keytruda + epacadostat Metastatic … -
List item
National expert: Hugues Malonne, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 81.15 KB | PDF
- Curriculum Vitae - 35.02 KB | PDF
Januvia - Isentress - Keytruda - Noxafil Diabetes (type … -
List item
Workshop on the challenges for the approval of anti-cancer immunotherapeutic drugs
European Medicines Agency, London, UK, from 04/02/2016 to 05/02/2016, Last updated: 08/04/201608/04/2016 Generic Presentation - KEYTRUDA® (pembrolizumab): melanoma … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021
CHMP, Last updated: 21/05/2021Icandra, Jalra, Jardiance, Keytruda, Opdivo, Spherox, Xiliarx … -
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,
, Revision: 17, Authorised, Last updated: 17/06/2022
-
List item
Human medicine European public assessment report (EPAR): Jemperli (updated)
dostarlimab, Endometrial Neoplasms
Date of authorisation: 21/04/2021,
, 
, Revision: 3, Authorised, Last updated: 10/06/2022
-
List item
Human medicine European public assessment report (EPAR): Yervoy
Ipilimumab, Melanoma; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Mesothelioma, Malignant; Colorectal Neoplasms
Date of authorisation: 13/07/2011, Revision: 48, Authorised, Last updated: 12/05/2022 -
List item
Human medicine European public assessment report (EPAR): Cotellic (updated)
cobimetinib hemifumarate, Melanoma
Date of authorisation: 20/11/2015, Revision: 12, Authorised, Last updated: 14/06/2022 -
List item
Human medicine European public assessment report (EPAR): Gavreto (updated)
pralsetinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 18/11/2021,, , Revision: 3, Authorised, Last updated: 10/06/2022
-
List item
Human medicine European public assessment report (EPAR): Rybrevant
amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021,, , Authorised, Last updated: 04/02/2022
-
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Mesothelioma; Colorectal Neoplasms
Date of authorisation: 19/06/2015, Revision: 49, Authorised, Last updated: 10/05/2022 -
List item
Human medicine European public assessment report (EPAR): Lenvima
lenvatinib mesilate, Thyroid Neoplasms
Date of authorisation: 28/05/2015,, , Revision: 16, Authorised, Last updated: 01/12/2021
-
List item
Human medicine European public assessment report (EPAR): Padcev
Enfortumab vedotin, Carcinoma, Transitional Cell; Urologic Neoplasms
Date of authorisation: 13/04/2022,, Authorised, Last updated: 18/05/2022
-
List item
Human medicine European public assessment report (EPAR): Cabometyx (updated)
cabozantinib (s)-malate, Carcinoma, Renal Cell; Carcinomas, Hepatocellular
Date of authorisation: 09/09/2016,, Revision: 14, Authorised, Last updated: 09/06/2022
-
List item
Human medicine European public assessment report (EPAR): Mekinist
trametinib, Melanoma
Date of authorisation: 30/06/2014, Revision: 27, Authorised, Last updated: 05/05/2022 -
List item
Human medicine European public assessment report (EPAR): Tafinlar
dabrafenib mesilate, Melanoma
Date of authorisation: 26/08/2013, Revision: 27, Authorised, Last updated: 09/12/2021 -
List item
Withdrawn application: Balimek
binimetinib, date of withdrawal: 04/01/2018, Initial authorisation, Last updated: 27/03/2018 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 17/06/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 31/05/20228 2.3.1. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109 … -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 04/07/2022